Manufacturer of Controlled Substances; Notice of Application, 10683 [05-4228]

Download as PDF 10683 Federal Register / Vol. 70, No. 42 / Friday, March 4, 2005 / Notices Dated: February 22, 2005. William J. Walker, Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration. [FR Doc. 05–4229 Filed 3–3–05; 8:45 am] Dated: February 23, 2005. William J. Walker, Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration. [FR Doc. 05–4228 Filed 3–3–05; 8:45 am] BILLING CODE 4410–09–P BILLING CODE 4410–09–P DEPARTMENT OF JUSTICE DEPARTMENT OF JUSTICE Drug Enforcement Administration Drug Enforcement Administration Manufacturer of Controlled Substances; Notice of Application Manufacturer of Controlled Substances; Notice of Application Pursuant to Section 1301.33(a) of Title 21 of the Code of Federal Regulations (CFR), this is notice that on November 9, 2004, Siegfried (USA), Inc., Industrial Park Road, Pennsville, New Jersey 08070, made application by renewal to the Drug Enforcement Administration (DEA) for registration as a bulk manufacturer of the basic class of controlled substances listed in Schedule II: Drug Schedule Amphetamine (1100) .................... Methylphenidate (1724) ................ Ambobarbital (2125) ..................... Pentobarbital (2270) ..................... Secobarbital (2315) ...................... Glutethimide (2550) ...................... Codeine (9050) ............................. Hydrocodone (9193) ..................... Methadone (9250) ........................ Methadone Intermediate (9254) ... Dextropropoxyphene, bulk (nondosage form) (9273). II II II II II II II II II II II The company plans to manufacture the listed controlled substances in bulk for distribution to its customers. Any other such applicant and any person who is presently registered with DEA to manufacture such substances may file comments or objections to the issuance of the proposed registration pursuant to 21 CFR 1301.33(a). Any such written comments or objections being sent via regular mail may be addressed, in quintuplicate, to the Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration, Washington, DC 20537, Attention: DEA Federal Register Representative, Liaison and Policy Section (ODL); or any being sent via express mail should be sent to DEA Headquarters, Attention: DEA Federal Register Representative/ODL, 2401 Jefferson-Davis Highway, Alexandria, Virginia 22301; and must be filed no later than May 3, 2005. VerDate jul<14>2003 19:07 Mar 03, 2005 Jkt 205001 Pursuant to 21 CFR 1301.33(a), Title 21 of the Code of Federal Regulations (CFR), this is notice that on December 21, 2004, Sigma Aldrich Research Biochemicals, Inc., 1–3 Strathmore Road, Natick, Massachusetts 01760, made application by letter to the Drug Enforcement Administration (DEA) for registration as a bulk manufacturer of the basic classes of controlled substances listed in Schedules I and II: Drug Schedule Cathinone (1235) .......................... Methcathinone (1237) ................... Aminorex (1585) ........................... Alpha-ethyltryptamine (7249) ........ Lysergic acid diethylamide (7315) Tetrahydrocannabinols (7370) ...... 4-Bromo-2,5-dimethoxy-amphetamine (7391). 4-Bromo-2,5dimethoxyphenethylamine (7392). 2,5-Dimethoxyamphetamine (7396). 3,4-Methylenedioxyamphetamine (7400). N-Hydroxy-3,4methylenedioxyamphetamine (7402). 3,4-Methylenedioxy-Nethylamphetamine (7404). 3,4Methylenedioxymethamphetamine (MDMA) (7405). 1-[1-(2Thienyl)cyclohexyl]piperidine (TCP) (7470). Heroin (9200) ................................ Normorphine (9313) ...................... Amphetamine (1100) .................... Methamphetamine (1105) ............. 1-Phenylcyclohexylamine (7460) .. Phencyclidine (7471) .................... Cocaine (9041) ............................. Codeine (9050) ............................. Diprenorphine (9058) .................... Ecgonine (9180) ........................... Levomethorphan (9210) ............... Levorphanol (9220) ....................... Meperidine (9230) ......................... Metazocine (9240) ........................ Methadone (9250) ........................ Morphine (9300) ........................... Thebaine (9333) ........................... Levo-alphacetylmethadol (9648) .. PO 00000 Frm 00093 Fmt 4703 Sfmt 4703 I I I I I I I Drug Carfentanil (9743) ......................... Fentanyl (9801) ............................. Schedule II II The company plans to manufacture the listed controlled substances in bulk for laboratory reference standards. Any other such applicant and any person who is presently registered with DEA to manufacture such a substance may file comments or objections to the issuance of the proposed registration pursuant to 21 CFR 1301.33(a). Any such written comments or objections being sent via regular mail may be addressed, in quintuplicate, to the Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration, Washington, DC 20537, Attention: DEA Federal Register Representative, Liaison and Policy Section (ODL); or any being sent via express mail should be sent to DEA Headquarters, Attention: DEA Federal Register Representative/ODL, 2401 Jefferson-Davis Highway, Alexandria, Virginia 22301; and must be filed no later than May 3, 2005. Dated: February 23, 2005. William J. Walker, Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration. [FR Doc. 05–4226 Filed 3–3–05; 8:45 am] BILLING CODE 4410–09–P I I DEPARTMENT OF LABOR I Office of the Secretary I Submission for OMB Review: Comment Request I February 24, 2005. I I I I II II II II II II II II II II II II II II II II The Department of Labor (DOL) has submitted the following public information collection requests (ICRs) to the Office of Management and Budget (OMB) for review and approval in accordance with the Paperwork Reduction Act of 1995 (Pub. L. 104–13, 44 U.S.C. chapter 35). A copy of each ICR, with applicable supporting documentation, may be obtained by contacting Darrin King on 202–693– 4129 (this is not a toll-free number) or e-mail: king.darrin@dol.gov. Comments should be sent to Office of Information and Regulatory Affairs, Attn: OMB Desk Officer for the Employee Benefits Security Administration (EBSA), Office of Management and Budget, Room 10235, Washington, DC 20503, (202) 395–7316 (this is not a toll-free number), within 30 days from the date of this publication in the Federal Register. E:\FR\FM\04MRN1.SGM 04MRN1

Agencies

[Federal Register Volume 70, Number 42 (Friday, March 4, 2005)]
[Notices]
[Page 10683]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 05-4228]


-----------------------------------------------------------------------

DEPARTMENT OF JUSTICE

Drug Enforcement Administration


Manufacturer of Controlled Substances; Notice of Application

    Pursuant to Section 1301.33(a) of Title 21 of the Code of Federal 
Regulations (CFR), this is notice that on November 9, 2004, Siegfried 
(USA), Inc., Industrial Park Road, Pennsville, New Jersey 08070, made 
application by renewal to the Drug Enforcement Administration (DEA) for 
registration as a bulk manufacturer of the basic class of controlled 
substances listed in Schedule II:

------------------------------------------------------------------------
                    Drug                               Schedule
------------------------------------------------------------------------
Amphetamine (1100).........................  II
Methylphenidate (1724).....................  II
Ambobarbital (2125)........................  II
Pentobarbital (2270).......................  II
Secobarbital (2315)........................  II
Glutethimide (2550)........................  II
Codeine (9050).............................  II
Hydrocodone (9193).........................  II
Methadone (9250)...........................  II
Methadone Intermediate (9254)..............  II
Dextropropoxyphene, bulk (non-dosage form)   II
 (9273).
------------------------------------------------------------------------

    The company plans to manufacture the listed controlled substances 
in bulk for distribution to its customers.
    Any other such applicant and any person who is presently registered 
with DEA to manufacture such substances may file comments or objections 
to the issuance of the proposed registration pursuant to 21 CFR 
1301.33(a).
    Any such written comments or objections being sent via regular mail 
may be addressed, in quintuplicate, to the Deputy Assistant 
Administrator, Office of Diversion Control, Drug Enforcement 
Administration, Washington, DC 20537, Attention: DEA Federal Register 
Representative, Liaison and Policy Section (ODL); or any being sent via 
express mail should be sent to DEA Headquarters, Attention: DEA Federal 
Register Representative/ODL, 2401 Jefferson-Davis Highway, Alexandria, 
Virginia 22301; and must be filed no later than May 3, 2005.

    Dated: February 23, 2005.
William J. Walker,
Deputy Assistant Administrator, Office of Diversion Control, Drug 
Enforcement Administration.
[FR Doc. 05-4228 Filed 3-3-05; 8:45 am]
BILLING CODE 4410-09-P